News | Radiopharmaceuticals and Tracers | March 14, 2019

Researchers Create New Method for Developing Cancer Imaging Isotopes

New method produces high-purity zirconium-89, a diagnostic radionuclide used to image cancerous tumors

Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

March 14, 2019 — A team of researchers at the University of Washington announced they developed a new automated system for producing zirconium-89, a diagnostic radionuclide used for cancer tumor imaging.

Ideal for cancer tumor imaging, zirconium-89 lasts long enough in the body to find tumors and be imaged using positron emission tomography (PET) scans. Producing this useful radionuclide requires commonly found low-energy cyclotrons. The researchers produced zirconium-89 by proton beam irradiation of yttrium metal foils at the university’s 11-MeV cyclotron. They then transported the foils to researchers at the Pacific Northwest National Laboratory. The research team developed an automated dual column system that dissolved the foil targets and isolated the zirconium-89 from the dissolved yttrium target (and metal contaminants found in the yttrium metal). The process consistently generated a highly concentrated and pure solution of zirconium-89 that demonstrated excellent binding to deferoxamine, a radionuclide-binding ligand frequently used in tumor-targeting molecules. A patent has been applied for this novel purification method.

As the zirconium-89 supply is currently meeting demand, this is not an isotope sold through the U.S. Department of Energy (DOE) Isotope Program. However, this work, supported by the DOE Isotope Program, shows that zirconium-89 can be produced on lower energy (and more abundant) cyclotrons with a simple target design. The new automated approach could make high-quality batches more available and reduce exposure for radiation workers. Also, the approach offers a high chemical yield and low metal ion impurities, minimizing interference with tumor targeting.

This work was funded by the Department of Energy, Office of Science, Office of Nuclear Physics, Isotope Development and Production for Research and Applications subprogram. Funding was also provided by the National Institutes of Health. The researchers used the CT/Eclipse/111 cyclotron at the University of Washington.

For more information: www.science.energy.gov

Publications

J.M. Link, K.A. Krohn, and M.J. O’Hara, “A simple thick target for production of 89Zr using an 11MeV cyclotron.” Applied Radiation and Isotopes 122, 211 (2017). [DOI: 10.1016/j.apradiso.2017.01.037]

M.J. O’Hara, N.J. Murray, J.C. Carter, C.M. Kellogg, and J.M. Link, “Hydroxamate column-based purification of zirconium-89 (89Zr) using an automated fluidic platform.” Applied Radiation and Isotopes 132, 85 (2018). [DOI: 10.1016/j.apradiso.2017.10.048]

M.J. O’Hara, N.J. Murray, J.C. Carter, and S.S. Morrison, “Optimized anion exchange column isolation of zirconium-89 (89Zr) from yttrium cyclotron target: Method development and implementation on an automated fluidic platform.” Journal of Chromatography A 1545, 48 (2018). [DOI: 10.1016/j.chroma.2018.02.053]

M.J. O’Hara, N.J. Murray, J.C. Carter, C.M. Kellogg, and J.M. Link, “Tandem column isolation of zirconium-89 from cyclotron bombarded yttrium targets using an automated fluidic platform: Anion exchange to hydroxamate resin columns.” Journal of Chromatography A 1567, 37 (2018). [DOI: 10.1016/j.chroma.2018.06.035]

Related Content

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Blue Earth Diagnostics Expands Access to Axumin in Europe
News | Radiopharmaceuticals and Tracers | May 13, 2019
Blue Earth Diagnostics announced expanded access to the Axumin (fluciclovine (18F)) imaging agent in Europe. The first...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

Image courtesy of Amen Clinics

News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
Novel Artificial Intelligence Method Predicts Future Risk of Breast Cancer
News | Artificial Intelligence | May 08, 2019
Researchers from two major institutions have developed a new tool with advanced artificial intelligence (AI) methods to...
American Society of Breast Surgeons Issues Risk-based Screening Mammography Guidelines
News | Mammography | May 03, 2019
The American Society of Breast Surgeons (ASBrS) has released the first screening mammography guidelines based on a...
A 3-D printed tungsten X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | April 29, 2019 | By Steve Jeffery
In ...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...